• Contact
  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog
Albumedix Albumedix' Patent Portfolio

Albumedix' Patent Portfolio

Albumedix’ patent portfolio includes the following families:

Albumedix’ patent portfolio includes the following families:

WO2004/009819 Gene and polypeptide sequences

WO2005/068489 Process for producing human serum albumin by heating in presence of divalent cation

WO2008/007146 Process for preparing particles of proteinaceous material

WO2010/092135 Albumin variants and conjugates

WO2011/051489 Albumin variants

WO2011/124718 Albumin derivatives and variants

WO2010/128142 Method for purifying albumin

WO2012/150319 Albumin variants

WO2013/006675 Albumin formulation and use

WO2013/075066 Proteins with improved half-life and other properties

WO2013/135896 Albumin variants

WO2014/072481 Albumin variants

WO2017/029407 Albumin variants and conjugates

WO2017/112847 Improved protein expression strains

WO2018/065491 Uses of recombinant yeast-derived albumin (for example in cryopreservation)

WO2018/234349 Improved protein expression strains

WO2021/111143 Methods and compositions produced thereby

Last updated: 01-MAR-2022

CONTACT

Albumedix Ltd.
Mabel Street
The Meadows
Nottingham
NG2 3ED, United Kingdom
Tel: +44 115 9553379
info@albumedix.com

 

Albumedix - Dedicated to Better Health

Albumedix is a science-driven company and recognized leader of best-in-class albumin-enabled solutions. Established in the UK in 1984, with a mission to empower excellence, Albumedix has supported its life-science partners to deliver hundreds of million safe doses of clinical and marketed therapeutics, globally. Albumedix’ solutions include the world’s only USP-NF compliant recombinant human albumin (Recombumin®), client-centric development and compliance services and drug-enhancing technologies (Veltis®). By always striving for more and collaboratively challenging status quo, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

 

Privacy | Cookies | Patent Portfolio

ALBUMEDIX, the ALBUMEDIX LOGO, DEDICATED TO BETTER HEALTH and marks such as RECOMBUMIN and VELTIS are trademarks of Albumedix. Albumedix© Copyright 2018

FOLLOW US

  • Albumin
    • Albumin
    • Recombumin® products
    • Sample page
  • Solutions
    • Recombumin® products
    • Compliance services
    • Innovation services
    • Veltis technology
  • Applications
    • Cell therapy
    • Gene therapy
    • Vaccine stabilization
    • Medical device coating
    • Protein & peptide formulation
    • Covid-19
  • About
    • About Albumedix
    • Management
    • Partnering
      • R&D collaborations
      • Pipeline
    • Careers
    • CSR
    • FAQ
  • Media
    • Scientific Library
    • News & Events
    • Blog

We use cookies on our website to improve the website and your experience.

Read more